XTL Biopharmaceuticals Ltd. (XTLB.TA)
XTL Biopharmaceuticals Ltd. operates in the Biotechnology industry of the Healthcare sector, headquartered in Ramat Gan, TA, IL. The stock last traded at $2.10, up 0.00% on the session, giving a market capitalisation of $19.9M. Its beta of 0.55 implies it has historically moved less than the broad market.
XTL Biopharmaceuticals Ltd. is a biopharmaceutical firm dedicated to sourcing and advancing medicinal products aimed at treating autoimmune conditions. Its principal experimental compound, hCDR1, is primed for Phase II clinical studies, addressing systemic lupus erythematosus and Sjogren's syndrome. The company operates under a licensing agreement with Yeda Research and Development Company Limited, granting it rights for the research, development, and commercialization of hCDR1 across numerous therapeutic applications. Originally incorporated in 1993 as Xenograft Technologies Ltd., the entity rebranded as XTL Biopharmaceuticals Ltd. in July 1995 and is currently headquartered in Ramat Gan, Israel.
XTL Biopharmaceuticals Ltd. is most often compared with the following Healthcare names: